Ash Stevens to Manufacture Amotosalen API
PTSM: Pharmaceutical Technology Sourcing and Management
FDA has approved the Ash Steven’s manufacturing facility in Riverview, MI for the manufacture of Amotosalen.
Ash Stevens, a provider of global contract pharmaceutical drug substance development and API manufacturing services, announced that FDA has approved the company’s manufacturing facility in Riverview, MI for the manufacture of Amotosalen, the API in Cerus Corporation's INTERCEPT Blood System. The INTERCEPT Blood System recently received FDA approval for ex vivo preparation of pathogenreduced plasma and platelet components in order to reduce the risk of transfusion-transmitted infection.
This represents ASI’s twelfth manufacturing approval for an innovator or new chemical entity drug.
Source: Ash Stevens
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
